Invivyd, Inc. (NASDAQ:IVVD – Get Free Report) saw a significant decline in short interest in the month of September. As of September 30th, there was short interest totalling 6,810,000 shares, a decline of 8.0% from the September 15th total of 7,400,000 shares. Currently, 9.4% of the shares of the company are short sold. Based on an average daily trading volume, of 438,400 shares, the days-to-cover ratio is presently 15.5 days.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Invivyd in a research note on Tuesday, September 3rd.
Get Our Latest Analysis on IVVD
Hedge Funds Weigh In On Invivyd
Invivyd Stock Up 3.6 %
IVVD stock opened at $0.99 on Thursday. The business’s 50-day moving average price is $0.99 and its 200-day moving average price is $1.57. The stock has a market cap of $117.61 million, a P/E ratio of -0.53 and a beta of 0.63. Invivyd has a twelve month low of $0.81 and a twelve month high of $5.20.
Invivyd (NASDAQ:IVVD – Get Free Report) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.03). The firm had revenue of $2.26 million for the quarter, compared to analysts’ expectations of $4.91 million. On average, equities research analysts expect that Invivyd will post -0.6 earnings per share for the current fiscal year.
Invivyd Company Profile
Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.
Recommended Stories
- Five stocks we like better than Invivyd
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- 3 Healthcare Dividend Stocks to Buy
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- How to Invest in the FAANG Stocks
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Invivyd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivyd and related companies with MarketBeat.com's FREE daily email newsletter.